Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells

Nutrition and Cancer

Volumn 65, Issue 4, 2013, Pages 590-599

  Ghasemi, Reza ^a   Ghaffari, Seyed H ^a   Momeny, Majid ^a   Pirouzpanah, Saeed ^b   Yousefi, Mehdi ^c   Malehmir, Mohsen ^a   Alimoghaddam, Kamran ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANGPT2 PROTEIN; ATP6L PROTEIN; CAP2 PROTEIN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CLDN 10 PROTEIN; COMPLEMENTARY DNA; CORTACTIN; GELATINASE A; GELATINASE B; HK2 PROTEIN; KIAA0101 PROTEIN; MORTALIN; P21 ACTIVATED KINASE 1; PROTEIN P53; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILIBININ; SPINK1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUTATION; SILYMARIN;

EID: 84877943662     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.770043     Document Type: Article

References (69)

1. Altekruse, S F, Mcglynn, K A, and, Reichman, M E. 2009. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27: 1485-1491.
2. El-Serag, H B, and, Rudolph, K L. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132: 2557-2576.
3. Han, Y F, Zhao, J, Ma, L Y, Yin, J H, Chang, W J. 2011. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol, 17: 4258-4270.
4. Merat, S, Rezvan, H, Nouraie, M, Jamali, A, Assari, S. 2009. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med, 12: 225-231.
5. Qin, L X, Tang, Z Y, Ma, Z C, Wu, Z Q, Zhou, X D. 2002. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol, 8: 459-463.
6. Natsuizaka, M, Omura, T, Akaike, T, Kuwata, Y, Yamazaki, K. 2005. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol, 20: 1781-1787.
7. Tang, Z Y. 2001. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol, 7: 445-454.
8. Tanaka, S, and, Arii, S. 2011. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol, 46: 289-296.
9. Wang, S M, Ooi, L L, and, Hui, K M. 2007. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res, 13: 6275-6283.
10. Ou, D P, Yang, L Y, Huang, G W, Tao, Y M, Ding, X. 2005. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gastroenterol, 11: 2061-2066.
11. Saller, R, Meier, R, and, Brignoli, R. 2001. The use of silymarin in the treatment of liver diseases. Drugs, 61: 2035-2063.
12. Abenavoli, L, Capasso, R, Milic, N, and, Capasso, F. 2010. Milk thistle in liver diseases: past, present, future. Phytother Res, 24: 1423-1432.
13. Ramasamy, K, and, Agarwal, R. 2008. Multitargeted therapy of cancer by silymarin. Cancer Lett, 269: 352-362.
14. Varghese, L, Agarwal, C, Tyagi, A, Singh, R P, and, Agarwal, R. 2005. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res, 11: 8441-8448.
15. Deep, G, and, Agarwal, R. 2010. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev, 29: 447-463.
16. Lah, J J, Cui, W, and, Hu, K Q. 2007. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol, 13: 5299-5305.
17. Cui, W, Gu, F, and, Hu, K Q. 2009. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol, 15: 1943-1950.
18. Momeny, M, Khorramizadeh, M R, Ghaffari, S H, Yousefi, M, Yekaninejad, M S. 2008. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol, 591: 13-20.
19. Chuma, M, Sakamoto, M, Yasuda, J, Fujii, G, Nakanishi, K. 2004. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol, 41: 629-636.
20. Lee, T K, Poon, R T, Yuen, A P, Ling, M T, Wang, X H. 2006. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res, 12: 6910-6919.
21. Ding, R, Han, S, Lu, Y, Guo, C, Xie, H. 2010. Overexpressed Id-1 is associated with patient prognosis and HBx expression in hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther, 10: 299-307.
22. Yi, X, Luk, J M, Lee, N P, Peng, J, Leng, X. 2008. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics, 7: 315-325.
23. Yuan, R H, Jeng, Y M, Pan, H W, Hu, F C, Lai, P L. 2007. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res, 13: 5368-5376.
24. Ching, Y P, Leong, V Y, Lee, M F, Xu, H T, Jin, D Y. 2007. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res, 67: 3601-3608.
25. Li, X R, Ji, F, Ouyang, J, Wu, W, Qian, L Y. 2006. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol, 32: 1130-1134.
26. Lee, Y C, Pan, H W, Peng, S Y, Lai, P L, Kuo, W S. 2007. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer, 43: 736-744.
27. Zhang, C H, Xu, G L, Jia, W D, Li, J S, Ma, J L. 2012. Activation of STAT3 Signal pathway correlates with twist and e-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res, 174: 120-129.
28. Yuan, R H, Jeng, Y M, Chen, H L, Lai, P L, Pan, H W. 2006. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol, 209: 549-558.
29. Gong, L, Cui, Z, Chen, P, Han, H, Peng, J. 2012. Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol, 29: 909-914.
30. Yoshiji, H, Kuriyama, S, Noguchi, R, Yoshii, J, Ikenaka, Y. 2005. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut, 54: 1768-1775.
31. Shibata, R, Mori, T, Du, W, Chuma, M, Gotoh, M. 2006. Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis. Clin Cancer Res, 12: 5363-5368.
32. Uchida, H, Iwashita, Y, Sasaki, A, Shibata, K, Matsumoto, T. 2006. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol, 21: 161-168.
33. Schimanski, C C, Bahre, R, Gockel, I, Muller, A, Frerichs, K. 2006. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer, 95: 210-217.
34. Xiang, Z L, Zeng, Z C, Tang, Z Y, Fan, J, Zhuang, P Y. 2009. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer, 9. 176
35. Schimanski, C C, Bahre, R, Gockel, I, Junginger, T, Simiantonaki, N. 2006. Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol Rep, 16: 109-113.
36. Fujii, H, Itoh, Y, Yamaguchi, K, Yamauchi, N, Harano, Y. 2004. Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro. Biochem Biophys Res Commun, 322: 1052-1058.
37. Shimoda, M, Takahashi, M, Yoshimoto, T, Kono, T, Ikai, I. 2006. A homeobox protein, prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin Cancer Res, 12: 6005-6011.
38. Chin, K T, Zhou, H J, Wong, C M, Lee, J M, Chan, C P. 2005. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res, 33: 1859-1873.
39. Chang, P C, Chi, C W, Chau, G Y, Li, F Y, Tsai, Y H. 2006. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene, 25: 1991-2003.
40. Agarwal, C, Singh, R P, Dhanalakshmi, S, Tyagi, A K, Tecklenburg, M. 2003. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 22: 8271-8282.
41. Flaig, T W, Gustafson, D L, Su, L J, Zirrolli, J A, Crighton, F. 2007. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs, 25: 139-146.
42. Momeny, M, Malehmir, M, Zakidizaji, M, Ghasemi, R, Ghadimi, H. 2010. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs, 21: 252-260.
43. He, M, Zhao, M, Shen, B, Prise, K M, and, Shao, C. 2011. Radiation-induced intercellular signaling mediated by cytochrome-c via a p53-dependent pathway in hepatoma cells. Oncogene, 30: 1947-1955.
44. Gouas, D A, Shi, H, Hautefeuille, A H, Ortiz-Cuaran, S L, Legros, P C. 2010. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis, 31: 1475-1482.
45. Block, T M, Mehta, A S, Fimmel, C J, and, Jordan, R. 2003. Molecular viral oncology of hepatocellular carcinoma. Oncogene, 22: 5093-5107.
46. Cheung, S T, Leung, K L, Ip, Y C, Chen, X, Fong, D Y. 2005. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res, 11: 551-556.
47. Peng, S Y, Lai, P L, Pan, H W, Hsiao, L P, and, Hsu, H C. 2008. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep, 19: 1045-1053.
48. Yi, X LJ, Lee, N P, Peng, J, Leng, X, Guan, X Y. 2008. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics, 7: 315-325.
49. Blanc, JFLC, Plomion, C, Schmitter, J M, Bathany, K, Gion, J M. 2005. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics, 5: 3778-3789.
50. Shi, L, Zhang, S L, Li, K, Hong, Y, Wang, Q. 2008. NS5ATP9, a gene up-regulated by HCV NS5A protein. Cancer Lett, 259: 192-197.
51. Ou, D P, Tao, Y M, Tang, F Q, and, Yang, L Y. 2007. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer, 120: 1208-1214.
52. Chan, A C, Chok, K S, Yuen, W K, Chan, S C, Poon, R T. 2011. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg, 146: 675-681.
53. Kiyici, M, Yilmaz, M, Akyildiz, M, Arikan, C, Aydin, U. 2008. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc, 40: 1511-1517.
54. Lu, W J, Lee, N P, Kaul, S C, Lan, F, Poon, R T. 2011. Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer, 129: 1806-1814.
55. Lu, W J, Lee, N P, Kaul, S C, Lan, F, Poon, R T. 2011. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ, 18: 1046-1056.
56. Zhang, X, Ling, M T, Wong, Y C, and, Wang, X. 2007. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci, 98: 308-314.
57. Lee, T K, Man, K, Ling, M T, Wang, X H, Wong, Y C. 2003. Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis, 24: 1729-1736.
58. Li, W C, Ye, S L, Sun, R X, Liu, Y K, Tang, Z Y. 2006. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res, 12: 7140-7148.
59. Huang, F, and, Geng, X P. 2010. Chemokines and hepatocellular carcinoma. World J Gastroenterol, 16: 1832-1836.
60. Kim, Y, Yoon, J W, Xiao, X, Dean, N M, Monia, B P. 2007. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res, 67: 3583-3593.
61. Gou, L, Wang, W, Tong, A, Yao, Y, Zhou, Y. 2011. Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J Mol Med, 89: 817-827.
62. Hsieh, S Y, Huang, S F, Yu, M C, Yeh, T S, Chen, T C. 2010. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog, 49: 476-487.
63. Zhou, Q, Ching, A K, Leung, W K, Szeto, C Y, Ho, S M. 2011. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Int J Oncol, 38: 721-731.
64. Ip, Y C, Cheung, S T, Lee, Y T, Ho, J C, and, Fan, S T. 2007. Inhibition of hepatocellular carcinoma invasion by suppression of claudin-10 in HLE cells. Mol Cancer Ther, 6: 2858-2867.
65. Kim, W, Yoon, J H, Jeong, J M, Cheon, G J, Lee, T S. 2007. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther, 6: 2554-2562.
66. Guo, M, Li, J, Wan, D, and, Gu, J. 2006. KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma. BMC Cancer, 6 (109)
67. Lu, X, Qin, W, Li, J, Tan, N, Pan, D. 2005. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res, 65: 6843-6849.
68. Sakamoto, M, Effendi, K, and, Masugi, Y. 2010. Molecular diagnosis of multistage hepatocarcinogenesis. Jpn J Clin Oncol, 40: 891-896.
69. Sosa-Pineda, B, Wigle, J T, and, Oliver, G. 2000. Hepatocyte migration during liver development requires Prox1. Nat Genet, 25: 254-255.